Saposnik Gustavo, Di Legge Silvia, Webster Fiona, Hachinski Vladimir
Department of Clinical Neurological Sciences, London Health Science Center, The University of Western Ontario, London, Ontario, Canada.
Neurology. 2005 Oct 25;65(8):1169-74. doi: 10.1212/01.wnl.0000180687.75907.4b.
Major neurologic improvement at 24 hours after administration of recombinant tissue plasminogen activator (rt-PA) in acute stroke may predict good outcome at 3 months.
To identify predictors of major neurologic improvement at 24 hours after IV rt-PA administration and its relationship with outcome at 3 months.
The authors analyzed patients with acute stroke treated with IV rt-PA from two academic centers in London, Ontario, and 33 affiliated hospitals between 1999 and 2003. Major neurologic improvement was defined by a > or = 8-point improvement in NIH Stroke Scale (NIHSS) score or an NIHSS score of 0 or 1 at 24 hours. Good outcome was defined as a 3-month modified Rankin Scale of 0 to 1.
Of 219 patients with acute stroke treated with rt-PA, 61 (28%) had major neurologic improvement at 24 hours. Glucose levels < 8 mmol/L (OR 4.98, 95% CI 1.6 to 15.2), lack of cortical involvement on 24 hour CT scan (OR 3.97, 95% CI 1.87 to 8.43), and female sex (OR 2.4, 95% CI 1.12 to 5.13) were associated with major neurologic improvement after adjusting for covariates. Patients with major neurologic improvement had a shorter hospital stay (6.7 vs 14.3 days; p = 0.001). Major neurologic improvement was an independent predictor of good outcome at 3 months (OR 12.8, 95% CI 4.72 to 34.6).
Major neurologic improvement after rt-PA was observed in 28% of patients and independently predicted good outcome at 3 months. Female sex, glucose levels < 8 mmol/L, and absence of cortical involvement at 24 hours CT scan were associated with major neurologic improvement.
急性卒中患者静脉注射重组组织型纤溶酶原激活剂(rt-PA)后24小时出现主要神经功能改善可能预示3个月时预后良好。
确定静脉注射rt-PA后24小时主要神经功能改善的预测因素及其与3个月时预后的关系。
作者分析了1999年至2003年间在安大略省伦敦市的两个学术中心以及33家附属医院接受静脉rt-PA治疗的急性卒中患者。主要神经功能改善定义为美国国立卫生研究院卒中量表(NIHSS)评分改善≥8分或24小时时NIHSS评分为0或1分。良好预后定义为3个月时改良Rankin量表评分为0至1分。
在219例接受rt-PA治疗的急性卒中患者中,61例(28%)在24小时时出现主要神经功能改善。调整协变量后,血糖水平<8 mmol/L(比值比[OR]4.98,95%置信区间[CI]1.6至15.2)、24小时CT扫描无皮质受累(OR 3.97,95%CI 1.87至8.43)以及女性(OR 2.4,95%CI 1.12至5.13)与主要神经功能改善相关。出现主要神经功能改善的患者住院时间较短(6.7天对14.3天;p = 0.001)。主要神经功能改善是3个月时良好预后的独立预测因素(OR 12.8,95%CI 4.72至34.6)。
28%的患者在rt-PA治疗后出现主要神经功能改善,且独立预测3个月时预后良好。女性、血糖水平<8 mmol/L以及24小时CT扫描无皮质受累与主要神经功能改善相关。